Rosa Sottile

Rosa Sottile

Auto-generated profile, based on publicly available information

Rosa Sottile

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in The Journal of Immunology
Verified
Journal Article
Closed access
RTRossana Tallerico
Rossana Tallerico
MTMatilde Todaro
Matilde Todaro
Simone Di FrancoSimone Di Franco
Simone Di Franco
Cristina MaccalliCristina Maccalli
Cristina Maccalli
CGCinzia Garofalo
Cinzia Garofalo
ECEnnio Carbone
Ennio Carbone
Tumor cell populations have been recently proposed to be composed of two compartments: tumor-initiating cells characterized by a slow and asymmetrical growth, and the “differentiated” cancer cells with a fast and symmetrical growth. Cancer stem cells or cancer-initiating cells (CICs) play a crucial role in tumor recurrence. The resistance of CICs to drugs and irradiation often allows them to survive traditional therapy. NK cells are potent cytotoxic lymphocytes that can recognize tumor cells. In this study, we have analyzed the NK cell recognition of tumor target cells derived from the two cancer cell compartments of colon adenocarcinoma lesions. Our data demonstrate that freshly purified allogeneic NK cells can recognize and kill colorectal carcinoma–derived CICs whereas the non-CIC counterpart of the tumors (differentiated tumor cells), either autologous or allogeneic, is less susceptible to NK cells. This difference in the NK cell susceptibility correlates with higher expression on CICs of ligands for NKp30 and NKp44 in the natural cytotoxicity receptor (NCR) group of activating NK receptors. In contrast, CICs express lower levels of MHC class I, known to inhibit NK recognition, on their surface than do the “differentiated” tumor cells. These data have been validated by confocal microscopy where NCR ligands and MHC class I molecule membrane distribution have been analyzed. Moreover, NK cell receptor blockade in cytotoxicity assays demonstrates that NCRs play a major role in the recognition of CIC targets. This study strengthens the idea that biology-based therapy harnessing NK cells could be an attractive opportunity in solid tumors.

23 December 2013 in Biomacromolecules
Verified
Journal Article
Closed access
CGCinzia Garofalo
Cinzia Garofalo
GCGiovanna Capuano
Giovanna Capuano
RSRosa Sottile
Rosa Sottile
RTRossana Tallerico
Rossana Tallerico
Renata AdamiRenata Adami
Renata Adami
Daniela PappalardoDaniela Pappalardo
Daniela Pappalardo

24 September 2021 in Science Immunology
Verified
Journal Article
Closed access
RSRosa Sottile
Rosa Sottile
MPM. Kazim Panjwani
M. Kazim Panjwani
CLColleen M. Lau
Colleen M. Lau
ADAnthony F. Daniyan
Anthony F. Daniyan
KTKento Tanaka
Kento Tanaka
KHKatharine C. Hsu
Katharine C. Hsu
NKG2C + CD8 + T cells, found in 40% of HCMV-seropositive individuals, have lost BCL11B expression and adopt an innate-like identity.

3 February 2017 in OncoImmunology
Verified
Journal Article
Open access
RTRossana Tallerico
Rossana Tallerico
CCCostanza Maria Cristiani
Costanza Maria Cristiani
ESElina Staaf
Elina Staaf
CGCinzia Garofalo
Cinzia Garofalo
RSRosa Sottile
Rosa Sottile
ECEnnio Carbone
Ennio Carbone
Despite the success of immune checkpoint blockade in melanoma, the majority of patients do not respond. We hypothesized that the T and NK cell subset frequencies and expression levels of their receptors may predict responses and clinical outcome of anti-CTLA-4 treatment. We thus characterized the NK and T cell phenotype, as well as serum levels of several cytokines in 67 melanoma patients recruited in Italy and Sweden, using samples drawn prior to and during treatment. Survival correlated with low expression of the inhibitory receptor TIM-3 on circulating T and NK cells prior to and during treatment and with the increased frequency of mature circulating NK cells (defined as CD3−CD56dim CD16+) during treatment. Survival also correlated with low levels of IL-15 in the serum. Functional experiments in vitro demonstrated that sustained exposure to IL-15 enhanced the expression of PD-1 and TIM-3 on both T and NK cells, indicating a causative link between high IL-15 levels and enhanced expression of TIM-3 on these cells. Receptor blockade of TIM-3 improved NK cell-mediated elimination of melanoma metastasis cell lines in vitro. These observations may lead to the development of novel biomarkers to predict patient response to checkpoint blockade treatment. They also suggest that induction of additional checkpoints is a possibility that needs to be considered when treating melanoma patients with IL-15.

28 August 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
CSCaterina Scirgolea
Caterina Scirgolea
RSRosa Sottile
Rosa Sottile
MLMarco De Luca
Marco De Luca
ASAlberto Susana
Alberto Susana
SCSilvia Carnevale
Silvia Carnevale
ELEnrico Lugli
Enrico Lugli

1 June 2019 in Immunity
Verified
Journal Article
Closed access
NANicholas M. Adams
Nicholas M. Adams
CGClair D. Geary
Clair D. Geary
ESEndi K. Santosa
Endi K. Santosa
DLDianne Lumaquin
Dianne Lumaquin
JLJean-Benoît Le Luduec
Jean-Benoît Le Luduec
JSJoseph C. Sun
Joseph C. Sun